Status:
TERMINATED
Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes
Lead Sponsor:
Centre Jean Perrin
Conditions:
Metastatic Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
To evaluate response rate of cisplatin - metronomic cyclophosphamide treatment.
Eligibility Criteria
Inclusion
- Age \> 18 ans,
- Performance status \< 2,
- Patient with metastatic breast cancer stade IV triple negative histologically confirmed
- Measurable or not disease but radiologically evaluable (RECIST 1.1),
- Negative Hormonal Receptors (Estrogens and/or Progesterone), HER-2 negative (Score 0 or 1 by Immunochemistry (IHC), negative FISH if score IHC 2),
- Patient with a progression during or after an anthracyclines and/or taxanes treatment receiving in neo-adjuvant or adjuvant regimen according to a resistance defined as a documented disease progression in the last 12 month after the last dose of taxanes or anthracyclines,
- Patient non previously treated by platinum salts,
- Hematological Functions: Neutrophiles ≥ 1,5.109/L, Platelets ≥ 100.109/L, Leucocytes \> 3 000/mm3, Hb \> 9g/dL,
- Hepatic Functions : total Bilirubin ≤ 1,5 time upper normal value (UNV), ASAT ≤ 2 ,5 time UNV, ALAT ≤ 2,5 time UNV, Alkaline Phosphatase ≤ 2,5 time UNV (\< 5 time UNV if case of hepatic metastasis),
- Renal Functions: Creatinine Clearance ≥ 60 mL/min,
- Patient signed the consent study form,
- Patient affiliated to a social security regimen (law of 9 August 2004).
Exclusion
- Male Patients,
- Unknown hormonal Receptors
- Positive HER-2 (Score 3 in IHC or positive FISH)
- Pregnant or breastfeeding patient, or in age of pregnancy or predicting to be pregnant in the 6 months after the end of treatment,
- Patient not using contraceptive treatment during the treatment or after the 6 months after the end of treatment,
- Patient is a ward,
- Patient suffering from a non compatible disease with the enrollment in the study,
- Cardiac, renal, medullar, respiratory or hepatic insufficiency, clinically significant cardiovascular disease (including myocardiac infarct, unstable angina, symptomatic congestive heart failure, uncontrolled cardiac arrhythmia) \< 1 year before the study enrollment or randomisation,
- Patient with pulmonary lymphangitis or symptomatic pleural effusion (grade≥2), meningeal known carcinoma or symptoms of cerebromeningeal invasion, brain metastases unless treatment and stability for at least 4 weeks (no steroids or anti-convulsive).
- Uncontrolled diabetes,
- Psychiatric or neurological significant abnormality,
- Peripheric Neuropathy \> grade 2,
- Antecedent of hypersensibility to one of study treatment or one of used excipients,
- Urinary tract infection or acute hemorrhagic cystitis in progress
- Concomitant treatment with a medicine containing phenytoin or medication received in the context of a trial, or participation in another therapeutic clinical trial within \<30 days prior treatment with chemotherapy.
- Geographically unstable patient in the next 6 months or remaining distance to the treatment center making it difficult to follow in the study,
- Known history of abuse of narcotic or other drug or alcohol
- History of surgery within 28 days before the start of treatment,
- Patient unwilling or unable to comply with the requirements of the study.
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2016
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT01910870
Start Date
July 1 2013
End Date
September 1 2016
Last Update
May 18 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Jean Perrin
Clermont-Ferrand, France, 63011